Cell Therapy News Volume 22.18 | May 17 2021

    0
    43







    2021-05-17 | CTN 22.18


    Cell Therapy News by STEMCELL Technologies
    Vol. 22.18 – 17 May, 2021
    TOP STORY

    Autologous Ex Vivo
    Lentiviral Gene Therapy for Adenosine Deaminase Deficiency

    Scientists treated 50 patients with severe combined immunodeficiency due to adenosine deaminase (ADA) with an investigational gene therapy composed of autologous CD34+ hematopoietic stem and progenitor cells transduced ex vivo with a self-inactivating lentiviral vector encoding human ADA.
    [New England Journal of Medicine]

    AbstractPress Release


    Watch the webinar where Dr. Suzan Imren discusses factors affecting the balance between HSC self-renewal and leukemic transformation
    PUBLICATIONSRanked by the impact factor of the journal

    Generation
    of Hypoimmunogenic T Cells from Genetically Engineered Allogeneic Human Induced Pluripotent Stem Cells

    Researchers reported the generation of hypoimmunogenic cancer-antigen-specific T cells derived from induced pluripotent stem cells lacking β2-microglobulin, the class-II major histocompatibility complex transactivator and the natural killer cell-ligand poliovirus receptor CD155, and expressing single-chain MHC class-I antigen E.
    [Nature Biomedical Engineering]

    Abstract

    A
    Stem Cell Population at the Anorectal Junction Maintains Homeostasis and Participates in Tissue Regeneration

    The authors identified a population of Krt17+ basal cells with multipotent properties at the squamo-columnar anorectal junction that maintained a squamous epithelium during normal homeostasis and could participate in the repair of a glandular epithelium following tissue injury.
    [Nature Communications]

    Full Article

    Engineered Red Blood Cells as an Off-the-Shelf Allogeneic Anti-Tumor Therapeutic

    Scientists engineered red blood cells into artificial antigen-presenting cells presenting a peptide bound to the major histocompatibility complex I, the costimulatory ligand 4-1BBL, and interleukin-12.
    [Nature Communications]

    Full Article

    LILRB4
    Suppresses Immunity in Solid Tumors and Is a Potential Target for Immunotherapy

    The authors observed a high correlation in LILRB4 expression with other immune inhibitory receptors. After tumor challenge, LILRB4−/− mice and mice treated with anti-LILRB4 antibody showed reduced tumor burden and increased survival.
    [Journal of Experimental Medicine]

    Abstract

    Removal of CD276+
    Cells from Haploidentical Memory T-Cell Grafts Significantly Lowers the Risk of GVHD

    Analysis of CD45RA-depleted haploidentical mixed lymphocytes culture revealed insufficient suppression of alloresponses in the CD4+ compartment and identified CD276 as a marker for alloreactive memory Th1 T cells.
    [Bone Marrow Transplantation]

    Full Article

    Serum‐Derived
    Small Extracellular Vesicles from Diabetic Mice Impair Angiogenic Property of Microvascular Endothelial Cells: Role of EZH2

    Investigators studied the role of serum‐derived small extracellular vesicles in diabetes mellitus–impaired microvascular endothelial cell function.
    [Journal of the American Heart Association]

    Full Article

    Isolation
    and Expansion of Thymus-Derived Regulatory T Cells for Use in Pediatric Heart Transplant Patients

    High levels of FOXP3, CTLA4 and CD25 expression, demethylation of the FOXP3 promoter and high suppressive ability were found with no differences between Tregs and RA+Tregs.
    [European Journal of Immunology]

    Abstract

    A
    Novel Non-Viral Delivery Method That Enables Efficient Engineering of Primary Human T Cells for Ex
    Vivo
    Cell Therapy Applications

    The Solupore system was used to deliver mRNA and CRISPR/Cas9 guide RNA ribonucleoprotein cargos to T cells, and efficiency was measured by flow cytometry.
    [Cytotherapy]

    Full Article


    Science is demanding. That's why scientists work smart.
    REVIEWS

    The Therapeutic Potential of Hematopoietic Stem Cells in Bone Regeneration

    Investigators highlight the influence of hematopoeitic stem cells in the bone repair process, mainly through the promotion of osteogenesis and angiogenesis at the bone injury site.
    [Tissue Engineering Part B-Reviews]

    Abstract

    Brief In Vitro IL-12 Conditioning of CD8+
    T Cells for Anticancer Adoptive T Cell Therapy

    Scientists summarize studies that indicate the superiority of IL-12 as a potential cytokine for conditioning T cells for adoptive cell therapy.
    [Cancer Immunology Immunotherapy]

    Abstract

    INDUSTRY AND POLICY NEWS

    BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases

    BlueRock Therapeutics LP, FUJIFILM Cellular Dynamics, Inc., and Opsis Therapeutics, LLC announced that they have entered into a strategic research and development (R&D) alliance. As part of the alliance, the companies will combine their collective expertise to discover and develop off-the-shelf iPS cell therapies for ocular diseases.
    [BlueRock Therapeutics LP]

    Press Release

    FEATURED EVENT

    World Stem Cell Summit

    June 14 – 18, 2021
    Virtual

    >
    See All Events

    JOB OPPORTUNITIES

    Research Associate – Regenerative Medicine and Gene Therapy

    University of California – Davis, California, United States

    Postdoctoral
    Associate – Immunotherapy, Genomic Instability, Anti-Tumor Immunity

    Baylor College of Medicine – Houston, Texas, United States

    Senior
    Researcher – Clinical Genome Editing

    St. Jude Children’s Research Hospital – Memphis, Tennessee, United States

    Assistant,
    Associate, Full Professor – Stem Cell Biology and Regenerative/Restorative Medicine

    Stanford University – Stanford, California, United States

    Postdoctoral Researcher Fellowships – Center for Stem Cell and Regenerative Medicine

    Zhejiang University – Zhejiang, China

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Science News Cell Therapy News
    Archives
    Contact Us
    Cell Therapy News Twitter